Product Code: RP-ID-10163608 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10163608
Market Overview:
Antacid Market Size study, by Drug Class (Proton Pump Inhibitor, H2 Antagonist, And Acid Neutralizers), by Formulation (Tablet, Liquid, And Powder) and Regional Forecasts 2019-2026
Antacid Market is valued approximately USD 6.13 billion in 2018 and is anticipated to grow with a healthy growth rate of more than 3.9% over the forecast period 2019-2026. The growingincrease prevalence of gastric diseases has led the healthcare and pharmaceuticals providers towards the development of more enhanced gastric solution to get relief from acidity and heartburns. Antacids are the class of drugs thatwhich reduces gastric acidity resulting in the increase pH of the stomach and duodenum. The growing prevalence of gastric diseases among geriatric population has led to the increase in demand for antacids. The advancement of e-commerce industry coupled with the consumer preference for online medication due to ease of availability of drugs and home delivery services has propelled the demand for antacids. The increasing adoption of self-medication and ease of availability of various over-the-counter antacids has increased the market share of antacids. Moreover, the population of Gastroesophageal reflux disease, or GERD, has increased significantly resulting in the growingincreased demand for antacids. The various factors leading to the gastric diseases are unhealthy diet, lack of proper sleep, and lack of physical activities. This hasve resulted in the accelerated market share of antacids.
The regional analysis of Antacid market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. Asia Pacific region is expected to register considerable growth over the forecast period owing to consumer awareness, rising investment by market players and growing disposable income have increased the market share of antacids. Moreover, availability of effective treatment methods has fostered the demand for antacids.
Major market player included in this report are:
GlaxoSmithKline plc
Bayer AG
Boehringer Ingelheim International GmbH
Sanofi
Pfizer Inc.
Abbott Laboratories
Dabur India Ltd.
GlaxoSmithKline plc
Sun Pharmaceuticals Ltd.
Procter & Gamble
Piramal Enterprises
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
H2 Antagonist
Proton pump inhibitors
Acid neutralizers
By Formulation:
Tablet
Liquid
Powder
By Region:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026
Target Audience of the Antacid Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Bayer AG
Boehringer Ingelheim International GmbH
Sanofi
Pfizer Inc.
Abbott Laboratories
Dabur India Ltd.
GlaxoSmithKline plc
Sun Pharmaceuticals Ltd.
Procter & Gamble
Piramal Enterprises
Related Reports
Proof of Quality & Reliability
